Clostridium Difficile

You took antibiotics a few weeks ago. Now you're having watery diarrhea several times a day, with cramping, and it isn't letting up. This is the situation where the test is useful: is Clostridioides difficile, formerly Clostridium difficile, growing in your colon, and does the strain you're carrying have the genes to make the toxins that damage the bowel lining?

The stool test detects toxin genes by qPCR. qPCR is a DNA method that copies and detects bacterial genetic material in your stool sample. It is very good at telling you whether toxigenic C. difficile is present. What it cannot do on its own is tell you whether that bacterium is actually causing your symptoms. That distinction is the whole story of interpreting this result, and it is where most confusion starts.

What the Test Actually Detects

C. difficile is a bacterium that grows without oxygen and survives outside the body as a hardy spore. Under a microscope it has the staining pattern microbiologists call Gram-positive. Those spores are why it spreads readily in hospitals and resists alcohol hand rub and many routine cleaners. When spores reach your colon and the normal bacterial community there has been disrupted, they can turn into growing cells.

The damage comes from two proteins the bacterium secretes: toxin A and toxin B. These attack the cells lining the colon, producing diarrhea, inflammation, and in severe cases pseudomembranous colitis or toxic megacolon. Toxic megacolon is a dangerous widening of the bowel. Not every strain makes toxins. The qPCR test targets a toxin gene, usually tcdB, so a positive means you are carrying a strain that has the genetic capacity to produce toxin.

Carrying the gene and actively making toxin are two different states. The bacterium can sit in your gut producing little or no toxin and cause nothing at all. That is the gap this test cannot close by itself.

Carrying It Versus Being Sick From It

This is the single most important thing to understand about a positive result. Plenty of people carry toxigenic C. difficile without any illness whatsoever. Among hospitalized adults, roughly 3% to 26% are colonized at any given time, and during outbreaks that figure can reach half. Among asymptomatic infants 6 to 12 months old, about 41% test positive for any strain, and roughly 14% carry toxigenic strains.

A qPCR test cannot distinguish a carrier from someone with active infection. In one study of patients tested on a multiplex stool panel, 76% of those who tested positive by molecular methods had no detectable toxin in their stool. Treating all of them as infections means a lot of unnecessary antibiotics for diarrhea that had another cause entirely.

The practical consequence: a positive result in someone with formed stool, or someone whose diarrhea is clearly explained by laxatives or tube feeding, usually means colonization rather than infection. Guidelines are blunt about this and restrict testing to people with clinically significant diarrhea, conventionally three or more unformed stools in 24 hours with no obvious alternative explanation.

What the Toxin Test Adds

This is why a second test matters so much. Toxin enzyme immunoassays detect the actual toxin protein in stool, not just the gene. They are considerably less sensitive than qPCR, catching somewhere between roughly half and four-fifths of true cases depending on the assay, but they are highly specific, above 90% in most studies. In a symptomatic adult, detectable toxin makes active disease much more likely.

And the toxin result tracks outcomes in a way the gene result does not. In a study of more than 1,400 hospitalized adults, nearly all infection-related complications and deaths occurred in people who were toxin-positive. People who were PCR-positive but toxin-negative had outcomes much closer to people who tested negative altogether: shorter diarrhea, fewer complications. A separate study of adults with toxin-negative stools found shorter hospital stays and less exposure to high-risk antibiotics, though a subset did later develop toxin-positive disease.

If your qPCR is positive, check whether a toxin test was also run. Many laboratories now do this automatically, reflexing positive molecular results to a toxin assay. More than half of accredited labs use some form of multistep algorithm rather than molecular testing alone. Where hospitals have adopted reflex testing, hospital-onset infection rates dropped sharply, in one system from 0.352 to 0.115 cases per 1,000 patient-days, mostly by cutting treatment of people who were colonized rather than infected.

Who Actually Gets Sick

Antibiotic exposure is the dominant trigger. Antibiotics clear out the bacterial community that normally keeps C. difficile from expanding, and spores that would otherwise sit harmlessly get their opening. Older age, recent hospitalization, and multiple other illnesses all raise risk, and these same factors recur across more than 40 identified risk factors in the literature.

Acid-suppressing drugs matter too. Across multiple meta-analyses, proton pump inhibitors are associated with a higher risk of infection, with estimates ranging from roughly 65% higher to about double. A Danish study of community-associated cases found risk stayed elevated up to a year after stopping the drug. A dose-response meta-analysis found higher doses and longer durations carried more risk, though the exact mechanism and the threshold where it becomes clinically meaningful are still unsettled.

One group deserves specific mention. If you have inflammatory bowel disease, C. difficile turns up in roughly 8% of hospitalizations for flares in prospective series, and it is especially common in ulcerative colitis. The catch is that a flare and an infection look nearly identical from the outside, so clinical judgment alone cannot separate them. Testing at the time of a flare is standard practice, not an optional extra.

Recurrence and Mortality

About 20% to 30% of people who get infected will get it again. In a German cohort of roughly 12,000 cases, 19% had a recurrence, and recurrence raised the risk of serious complications. In a US cohort of nearly 4,000 patients, recurrence was linked to a significantly higher chance of dying within six months compared with people who did not recur. An English database study of more than 20,000 patients found both hospital-acquired and recurrent infection raised the risk of complications or death over the following year.

The mortality signal is substantial. A Swedish population study of 43,150 people with infection and 355,172 matched controls found infection was associated with a three- to seven-fold higher death rate, with the highest figures in hospital-acquired cases and during a first episode. Not every study agrees; a Japanese cohort of 566 hospitalized patients with clinically significant diarrhea found no increased mortality tied to infection after adjustment.

That apparent contradiction is worth resolving rather than leaving open. These studies measured different things. Population-wide database studies capture the sickest patients, where infection travels alongside advanced age, cancer, kidney disease, and hospitalization, and separating the infection's own contribution from everything else is difficult. The Japanese study restricted itself to patients who already had significant diarrhea, which is a fairer comparison and a narrower one. So treat the raw death-rate multiples as risk markers, not as pure cause-and-effect.

Predicting Who Will Do Badly

Some markers add information beyond the yes-or-no result. Fecal calprotectin reflects intestinal inflammation. It runs higher in people who go on to have recurrence, and in a study of 200 patients, calprotectin combined with the abundance of certain gut bacteria helped flag who was at risk. Fecal lactoferrin is another stool inflammation marker. It tracks with more severe disease and with ribotype 027, a strain type that tends to cause more aggressive illness.

A high white blood cell count and a low albumin both point toward more severe disease. Kidney dysfunction shows up repeatedly as a risk factor for both severity and recurrence. Older age and multiple coexisting conditions are the strongest predictors of dying in hospital, based on a nationwide Spanish study of nearly 346,000 patients.

Some laboratories report the qPCR cycle threshold. This number reflects how much bacterial DNA was in the sample, where lower means more. Low values predict toxin positivity with reasonable accuracy, and they track with more severe disease and higher mortality. This is useful context, not a standalone answer, and it still does not fully separate carriage from disease.

When Results Can Be Misleading

The biggest source of a misleading positive is not a lab error. It is testing the wrong person. If your stool is formed, if you started a laxative yesterday, or if you have another clear cause of diarrhea, a positive result most likely reflects colonization you were already carrying, not a new infection.

False negatives are a different problem, and a major driver is that treatment was started before the sample was collected. In a small prospective study, 4 of 9 patients who got empirical treatment for suspected infection had already converted to a negative test by the time their stool was collected. Conversion climbed with each day of therapy: about 14% after one day of treatment, 35% after two, 45% after three. If you are already on vancomycin or metronidazole for suspected infection, a negative result tells you very little.

Two smaller sources of error round out the picture. Rare strains with genetic variation at the spot the test's primers bind can slip past detection even when viable toxigenic bacteria are present. And repeat testing after a negative rarely helps: in one study, 97.5% of repeat tests done within seven days were still negative, so only a few percent of patients convert. Retesting is not the answer to a negative you distrust; a different test or a different diagnosis is.

Why the Result Is a Snapshot, Not a Trend

Most biomarkers reward tracking. This one does not. A qPCR result is a yes-or-no answer about a specific episode of illness, not a number that drifts over months. The organism is either there or it isn't, and repeating the test during the same episode of diarrhea adds almost nothing.

The exception is recurrence. If your symptoms come back weeks after finishing treatment, that is a new episode and it warrants a new test, along with a toxin assay, because roughly one in four people recur and recurrence carries real risk. But if you are still symptomatic partway through treatment, retesting is not helpful. The test can stay positive for a while after symptoms resolve, so a follow-up test to confirm cure is not recommended and can lead to pointless further treatment.

What is worth tracking, if you have had an episode, is the downstream picture: inflammation markers, albumin, kidney function, and your symptoms. Those change and they tell you whether you are recovering.

What to Do With a Positive Result

Start with the question the test cannot answer: do your symptoms fit? If you have three or more unformed stools a day with no alternative explanation, and especially if you took antibiotics in the past several weeks, this is an infection to treat, and you should be seen promptly. Fidaxomicin is now preferred in major guidelines for many initial episodes because it lowers relapse risk; oral vancomycin remains an accepted alternative and is still central for fulminant disease. Both require a prescription and clinical assessment for severity.

If the lab has not already done it, find out whether a toxin assay was run on your sample. A positive gene test with a positive toxin test is a much stronger signal of real disease. A positive gene test with a negative toxin test, in someone whose symptoms are mild and who has another plausible cause, often reflects carriage, though a subset of these patients do go on to develop toxin-positive disease and need close follow-up.

Several other findings change the urgency. Fever above 38.5 degrees Celsius, a markedly elevated white count, low albumin, or worsening kidney function all point toward severe disease and warrant same-day medical attention, not watchful waiting. Severe abdominal distension with pain is a red flag for toxic megacolon and needs emergency care. If you have inflammatory bowel disease, involve your gastroenterologist directly, since flare and infection can coexist and both need addressing.

After a second recurrence, treatment often shifts toward restoring the gut bacterial community. Fecal microbiota transplantation is recommended by European guidelines for multiple recurrences, and a network meta-analysis of randomized trials rated it the most effective treatment overall, with fidaxomicin the most effective antibiotic for preventing recurrence. Bezlotoxumab targets toxin B and reduces recurrence when given alongside standard treatment. These are specialist decisions, so an infectious disease or gastroenterology referral is reasonable after a second episode.